Cargando…

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates

Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Diep, Laetitia, Barbier, Vincent, Doussière, Marie, Touboul, Estelle, Jesson, Claire, Deprez, Valentine, Sobhy-Danial, Jean-Marc, Fardellone, Patrice, Goëb, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/
https://www.ncbi.nlm.nih.gov/pubmed/36294300
http://dx.doi.org/10.3390/jcm11205978
_version_ 1784817763797172224
author Diep, Laetitia
Barbier, Vincent
Doussière, Marie
Touboul, Estelle
Jesson, Claire
Deprez, Valentine
Sobhy-Danial, Jean-Marc
Fardellone, Patrice
Goëb, Vincent
author_facet Diep, Laetitia
Barbier, Vincent
Doussière, Marie
Touboul, Estelle
Jesson, Claire
Deprez, Valentine
Sobhy-Danial, Jean-Marc
Fardellone, Patrice
Goëb, Vincent
author_sort Diep, Laetitia
collection PubMed
description Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan–Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. Results: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. Conclusions: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept.
format Online
Article
Text
id pubmed-9604240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96042402022-10-27 Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates Diep, Laetitia Barbier, Vincent Doussière, Marie Touboul, Estelle Jesson, Claire Deprez, Valentine Sobhy-Danial, Jean-Marc Fardellone, Patrice Goëb, Vincent J Clin Med Article Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan–Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. Results: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. Conclusions: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept. MDPI 2022-10-11 /pmc/articles/PMC9604240/ /pubmed/36294300 http://dx.doi.org/10.3390/jcm11205978 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Diep, Laetitia
Barbier, Vincent
Doussière, Marie
Touboul, Estelle
Jesson, Claire
Deprez, Valentine
Sobhy-Danial, Jean-Marc
Fardellone, Patrice
Goëb, Vincent
Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title_full Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title_fullStr Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title_full_unstemmed Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title_short Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
title_sort comparison of rheumatoid arthritis patients’ 2-year infliximab, abatacept, and tocilizumab persistence rates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/
https://www.ncbi.nlm.nih.gov/pubmed/36294300
http://dx.doi.org/10.3390/jcm11205978
work_keys_str_mv AT dieplaetitia comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT barbiervincent comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT doussieremarie comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT touboulestelle comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT jessonclaire comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT deprezvalentine comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT sobhydanialjeanmarc comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT fardellonepatrice comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates
AT goebvincent comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates